ReviewNPJ schizophrenia2016
Early interventions in risk groups for schizophrenia: what are we waiting for?
Review in NPJ schizophrenia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Controlled Trials.Clinical drug investigation · 2025Pooled it
- Psychosis-like experiences and resilience: A systematic and critical review of the literature.Psychological services · 2022Pooled it
- Peripheral Biomarkers in Schizophrenia: A Meta-Analysis of Microarray Gene Expression Datasets.The international journal of neuropsychopharmacology · 2019Pooled it
- Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis.Schizophrenia bulletin · 2018Pooled it
- Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.Neuropsychopharmacology reports · 2019Trial
- Trajectories of Resilience-Related Traits and Their Impact on Health Outcomes in Schizophrenia: Results From a 4-Year Longitudinal Study.Schizophrenia bulletin · 2026Article
- The multiomics landscape of plasma exosomes in first-episode drug-naïve of schizophrenia.BMC psychiatry · 2025Article
- Pilot study of cerebrospinal fluid biomarkers reveals inflammatory changes in patients with paranoid schizophrenia.Scientific reports · 2025Article
- The awareness, characterization, and burden of Cognitive Impairment Associated with Schizophrenia (CIAS) in clinical practice: Results from a nationwide survey in Italy.Schizophrenia research. Cognition · 2025Article
- Familial High-Risk for Psychosis and Bipolar Disorder Amongst Youth in an Academic Healthcare System: A Real-World Assessment of Clinical Characteristics and Implications for Clinical Care.Early intervention in psychiatry · 2025Article
- Integrative genetic analysis: cornerstone of precision psychiatry.Molecular psychiatry · 2025Review
- Therapeutic potential of D-amino acid oxidase inhibitors for cognitive impairment associated with schizophrenia: learnings from luvadaxistat.The international journal of neuropsychopharmacology · 2024Review
- Acute optogenetic induction of the prodromal endophenotype of CA1 hyperactivity causes schizophrenia-related deficits in cognition and salience attribution.Schizophrenia (Heidelberg, Germany) · 2024Article
- Longitudinal Investigation of Auditory Dynamic Range Deficits in Early Psychosis and its Relationship to Negative Symptoms.Schizophrenia bulletin · 2023Article
- Disorganized Communication and Social Dysfunction in Schizophrenia: Emerging Concepts and Methods.Current psychiatry reports · 2023Review
- Enriched environment as a nonpharmacological neuroprotective strategy.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Epigenetic Targets in Schizophrenia Development and Therapy.Brain sciences · 2023Review
- The Inflammatory Signals Associated with Psychosis: Impact of Comorbid Drug Abuse.Biomedicines · 2023Review
- Review
- A narrative review of treatment interventions to improve cognitive performance in schizophrenia, with an emphasis on at-risk and early course stages.Psychiatry research · 2022Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Intervention strategies in adolescents at ultra high-risk (UHR) for psychosis are promising for reducing conversion to overt illness, but have only limited impact on functional outcome. Recent studies suggest that cognition does not further decline during the UHR stage. As social and cognitive impairments typically develop before the first psychotic episode and even years before the UHR stage, prevention should also start much earlier in the groups at risk for schizophrenia and other psychiatric disorders. Early intervention strategies could aim to improve stress resilience, optimize brain maturation, and prevent or alleviate adverse environmental circumstances. These strategies should urgently be tested for efficacy: the prevalence of ~1% implies that yearly ~22 in every 100,000 people develop overt symptoms of this illness, despite the fact that for many of them-e.g., children with an affected first-degree family member or carriers of specific genetic variants-increased risk was already identifiable early in life. Our current ability to recognize several risk groups at an early age not only provides an opportunity, but also implies a clinical imperative to act. Time is pressing to investigate preventive interventions in high-risk children to mitigate or prevent the development of schizophrenia and related psychiatric disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.